Hangzhou Tigermed Consulting Co (HKSE:03347) Change In Receivables : HK$0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Change In Receivables?

Hangzhou Tigermed Consulting Co's change in receivables for the quarter that ended in Mar. 2025 was HK$0 Mil. It means Hangzhou Tigermed Consulting Co's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Hangzhou Tigermed Consulting Co's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-1,086 Mil. It means Hangzhou Tigermed Consulting Co's Accounts Receivable increased by HK$1,086 Mil from Dec. 2023 to Dec. 2024 .

Hangzhou Tigermed Consulting Co's Accounts Receivable for the quarter that ended in Mar. 2025 was HK$1,239 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hangzhou Tigermed Consulting Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 67.40.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hangzhou Tigermed Consulting Co's liquidation value for the three months ended in Mar. 2025 was HK$-2,424 Mil.

Hangzhou Tigermed Consulting Co Change In Receivables Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Change In Receivables Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-168.66

-990.27

-970.70

-786.94

-1,085.78

Hangzhou Tigermed Consulting Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Hangzhou Tigermed Consulting Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Hangzhou Tigermed Consulting Co (HKSE:03347) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hangzhou Tigermed Consulting Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1238.824	/	1677.097	*	91
=	67.40

2. In Ben Graham's calculation of liquidation value, Hangzhou Tigermed Consulting Co's accounts receivable are only considered to be worth 75% of book value:

Hangzhou Tigermed Consulting Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1796.245	-	5169.125	+	0.75 * 1238.824	+	0.5 * 39.097
=	-2,424

Hangzhou Tigermed Consulting Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Executives

Sands Capital Management, Llc	2101 Beneficial owner
Sands Capital Management, Lp	2201 Interest of corporation controlled by you
Sands Family Trust, Llc	2201 Interest of corporation controlled by you
Sands Frank Melville Jr.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
F-j Sands Family I, Llc	2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd	2102 Investment manager
Ninety One Uk Limited	2102 Investment manager
Baillie Gifford & Co	2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines